Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 1,293 in Gilead Sciences

  1. $1,000 pill now hepatitis C treatment of choiceRead the original story w/Photo

    3 min ago | Park Record

    ... But clinical and commercial successes have triggered scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, a net margin of 56 percent. Two senior senators are ...

    Comment?

  2. $1,000 pill now hepatitis C treatment of choiceRead the original story w/Photo

    6 min ago | Red Bluff Daily News

    ... But clinical and commercial successes have triggered scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, a net margin of 56 percent. Two senior senators are ...

    Comment?

  3. In Europe, two drugs will compete to treat rare blood cancerRead the original story w/Photo

    7 hrs ago | Seattle Post-Intelligencer

    ... treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned. Last week, Gilead Sciences of Foster City won federal approval for Zydelig, its first cancer drug. It's playing catch-up with Imbruvica, which is sold ...

    Comment?

  4. Diplomat receives distribution contract for ZydeligARead the original story

    12 hrs ago | Freshnews

    ... management support and 24 hour access to patient care coordinators, nurses and pharmacists. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet ...

    Comment?

  5. Why Gilead Sciences (GILD) Stock Is Up TodayRead the original story w/Photo

    17 hrs ago | TheStreet.com

    ... company's new price target represents 41% upside from its opening price today. TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation: "We rate GILEAD ...

    Comment?

  6. Raising My $100 Price Target For Gilead Sciences On Sovaldi SalesRead the original story

    Monday Jun 30 | Seeking Alpha

    Gilead Sciences has been on a tear of late, rising more than 20% in the past three months on expectations of a stellar earnings report.

    Comment?

  7. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Friday Jul 25 | Business Wire

    ... voor recidiverende chronische lymfocytische leukemie, folliculair lymfoom en klein lymfocytisch lymfoom )--Gilead Sciences, Inc. (Nasdaq: GILD) kondigde vandaag aan dat de U.S. Food and Drug Administration (FDA) ZydeligA (idelalisib) 150 mg ...

    Comment?

  8. Creating Cures And Dividends Where None Existed Before With Gilead SciencesRead the original story w/Photo

    Saturday Jul 26 | GuruFocus.com

    ... for exceptional returns with limited risk. I think I have found that situation to exist today in shares of Gilead Sciences Inc. ( GILD ). Gilead is a biotech drug company focused on the development, marketing and distribution of drugs targeted at ...

    Comment?

  9. This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the MarkRead the original story w/Photo

    Saturday Jul 26 | The Motley Fool

    ... brooms Get out your brooms, because no company cleaned up this week when it comes to positive data more than Gilead Sciences ( ) . On Wednesday, the U.S. Food and Drug Administration announced that it had approved oral Zydelig (formerly idelalisib) ...

    Comment?

  10. EGPAF applauds new licensing agreement to improve access to HIV medication for childrenRead the original story w/Photo

    Friday Jul 25 | Medical News

    The Elizabeth Glaser Pediatric AIDS Foundation applauds the new licensing agreement between the Medicines Patent Pool and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate , a promising new HIV medication.

    Comment?

  11. Pricey Drug for Hepatitis C Brings Loud Criticism from ActivistsRead the original story w/Photo

    Friday Jul 25 | Voice of America

    ... most patients will cost $84,000. That has brought howls of protests from activists accusing California-based Gilead Sciences of charging extortionate prices. The dispute highlights the continuing conundrum afflicting medical research and spiraling ...

    Comment?

  12. New Licensing Agreement Could Improve Treatment Options for Children Living with HIVRead the original story

    Friday Jul 25 | PressReleasePoint

    Washington, D.C.-July 25, 2014- The Elizabeth Glaser Pediatric AIDS Foundation applauds the new licensing agreement between the Medicines Patent Pool and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate , a promising new HIV medication.

    Comment?

  13. Q2 Revenue Best Since 2012Read the original story

    Friday Jul 25 | Investor's Business Daily

    Earnings grew 6.5%. Health care revenue surged 9.8%, driven by and sales of its hep-C drug Sovaldi.

    Comment?

  14. Gilead Sciences, Inc. v. Natco Pharma Ltd.Read the original story

    Friday Jul 25 | JD Supra

    Case Name: Gilead Sciences, Inc. v. Natco Pharma Ltd. , 2013-1418, 2014 U.S. App.

    Comment?

  15. States Worry Price of Hepatitis C Drug Could Break the BankRead the original story

    Friday Jul 25 | News Max

    ... term as patients will avoid expensive hospitalizations and costly liver transplants. The makers of the drug, Gilead Sciences, believe the drug's effectiveness will eventually outweigh cost concerns, even as insurers and lawmakers are scrutinizing ...

    Comment?

  16. Science and Society: Let's Fight HIV and Hep C TogetherRead the original story w/Photo

    Friday Jul 25 | Q-Notes

    ... Conference on Thursday. The big story is that new and evolving hepatitis C (HCV) oral treatments such as Gilead Sciences' Sovaldi (sofosbuvir), achieve unprecedented cure rates of the virus that is a major cause of liver cirrhosis and cancer and is ...

    Comment?

  17. NAPSR news: Gilead reveals 2014 Q2 Report, sales soar for blockbuster drug SovaldiRead the original story

    Friday Jul 25 | PR Log

    Gilead Sciences, Inc. is a biopharmaceutical company whose main focus is centered on discovering, developing and commercializing innovative therapeutics in areas of unmet medical need.

    Comment?

  18. European Adopts Positive Opinion For Gilead Sciences, Inc.??'s...Read the original story

    Friday Jul 25 | BioSpace

    Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for ZydeligA , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)

    Comment?

  19. European CHMP Adopts Positive Opinion for Gilead's Zydelig ...Read the original story

    Friday Jul 25 | Investor's Business Daily

    Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorization Application for ZydeligA , a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular ... (more)

    Comment?

  20. $1,000-a-pill hepatitis C drug boosts Gilead's fortunesRead the original story w/Photo

    Friday Jul 25 | Medical News

    ... but could intensify concerns about society's ability to pay for it. The sales, announced on Wednesday by Gilead Sciences, were an increase from the $2.3 billion in the first three months of the year, the first full quarter of sales since the drug's ...

    Comment?